Michel, Maurice
Labenz, Christian
Armandi, Angelo
Kaps, Leonard
Kremer, Wolfgang Maximilian
Galle, Peter R.
Grimm, Daniel
Sprinzl, Martin
Schattenberg, Jörn M.
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Article History
Received: 4 January 2023
Accepted: 5 April 2023
First Online: 6 June 2023
Competing interests
: JMS reports Consultant: Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Genfit, Gilead Sciences, GSK, Heel GmbH, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Julius Clinical, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shinogi, Siemens Healthcare GmbH, Summit Clinical Research. Research Funding: Gilead Sciences, Boehringer Ingelheim, Nordic Bioscience, Siemens Healthcare GmbH. Speaker Honorarium: MedPublico GmbH, Boehringer Ingelheim. The other authors declare that they have no competing interests.